Patrick Jordan, Managing Partner and Chief Operating Officer at NovaQuest Capital Management has over 25 years of leadership in the healthcare industry across life sciences, data and analytics, payers and providers and specialty financing. Mr. Jordan currently serves as the interim Chief Executive Officer of Mycovia Pharmaceuticals, a NovaQuest portfolio company, and led the company to develop the first FDA-approved medication for an unmet medical need in women’s health.
An original member of the NovaQuest unit at its inception at Quintiles, Mr. Jordan originated, structured, and managed biopharma investments in the United States and on assignment to the United Kingdom. Over a 20-year career at Quintiles (now IQVIA), he led the company’s global accounts, oversaw over $1bn in annual client engagements, and instituted a managed partnership strategy that was recognized in Harvard Business Review. He was instrumental in the launch and leadership of a new business vertical servicing healthcare provider systems with health information analytics and technology services. In 2016, he led the transformation of clinical development with data analytics and global delivery processes, which was core to the $18bn merger of Quintiles and IMS Health. Rejoining NovaQuest in 2017, he leads the firm’s operations and is a member of the investment committee of the General Partner of NovaQuest Pharma Opportunities Fund V.
Mr. Jordan earned a BA from Duke University, MA from the University of Durham, United Kingdom MBA with a concentration in Health Sector Management from the Fuqua School of Business at Duke University.